3a,7a-Dihydro-1(3H)-isobenzofuranone | 77471-69-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 异苯并呋喃
• 英文名称: 3a,7a-Dihydro-1(3H)-isobenzofuranone
• 英文别名: 3a,7a-dihydro-3H-2-benzofuran-1-one
• CAS: 77471-69-3
• 化学式: C₈H₈O₂
• 分子量: 136.15
• InChiKey: LJZXCFXQZAVGGU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  10
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  3a,7a-Dihydro-1(3H)-isobenzofuranone 、 4-苯基-1,2,4-三唑啉-3,5-二酮 以88%的产率得到
  参考文献：
  名称：

  ASHKENAZI P.; GINSBURG D., TETRAHEDRON , 1977, 33, NO 11, 1345-1348

  摘要：

  DOI：

文献信息

• [EN] USE OF UREA VARIANTS AS AFFINITY LIGANDS<br/>[FR] UTILISATION DE VARIANTES D'UREES EN TANT QUE LIGANDS A AFFINITE
  申请人：AMERSHAM BIOSCIENCES AB

  公开号：WO2004039765A1

  公开（公告）日：2004-05-13

  The present invention relates to an IgG-binding compound, which more specifically has affinity for human IgGs of k-type and functional derivatives thereof. More specifically, the compound according to the invention comprises an N,N-alkylated urea moiety located between an aromatic part and another part, which is a linear or cyclic substituted or unsubstituted aliphatic group. The compound binds to a pocket-shaped binding site present on all human IgG k-Fabs, which site is located between the two domains (CH1 and CL) of its constant part. Accordingly, the compound according to the invention is a ligand for human IgGs of k-type, and consequently, the invention also relates to a separation matrix for affinity chromatography, which matrix comprises said compound, as well as to other uses of the compound.

  本发明涉及一种IgG结合化合物，更具体地具有对人类k型IgG及其功能衍生物的亲和力。具体而言，本发明的化合物包括位于芳香部分和另一部分之间的N，N-烷基化脲基团，该另一部分是线性或环状取代或未取代的脂肪族基团。该化合物结合到所有人类IgG k-Fab中存在的口袋状结合位点，该位点位于其常数部分的两个域（CH1和CL）之间。因此，本发明的化合物是人类k型IgG的配体，因此，本发明还涉及一种亲和层析的分离基质，该基质包括所述化合物，以及化合物的其他用途。
• NITROGEN HEXACYCLE COMPOUNDS AS INHIBITORS OF p97 COMPLEX
  申请人：Cleave Biosciences, Inc.

  公开号：US20160355503A1

  公开（公告）日：2016-12-08

  Nitrogen hexacycle compounds having an arylalkyl amine substituent at the P4 position and a substituted 5:6 bicyclic group at the P2 position of the nitrogen hexacycle as well as optional aliphatic, functional and/or aromatic components substituted at other positions of the nitrogen hexacycle, the aryl alkyl group and the 5:6 bicyclic group are disclosed. These compounds are inhibitors of the AAA proteasome complex containing p97 and are effective medicinal agents for treatment of diseases associated with p97 bioactivity such as cancer.

  本发明涉及一种氮六环化合物，其在P4位置具有芳基烷基胺取代基，在氮六环的P2位置具有取代的5:6双环基团，并在氮六环的其他位置，芳基烷基基团和5:6双环基团的其他位置上可选地取代有脂肪族、功能性和/或芳香性组分。这些化合物是AAA蛋白酶体复合物的p97抑制剂，并且是治疗与p97生物活性相关的疾病，如癌症的有效药物。
• Use of urea variants as affinity ligands
  申请人：Axen Andreas

  公开号：US20060014735A1

  公开（公告）日：2006-01-19

  The present invention relates to an IgG-binding compound, which more specifically has affinity for human IgGs of κ-type and functional derivatives thereof. More specifically, the compound according to the invention comprises an N,N-alkylated urea moiety located between an aromatic part and another part, which is a linear or cyclic substituted or unsubstituted aliphatic group. The compound binds to a pocket-shaped binding site present on all human IgG κ-Fabs, which site is located between the two domains (CH1 and CL) of its constant part. Accordingly, the compound according to the invention is a ligand for human IgGs of κ-type, and consequently, the invention also relates to a separation matrix for affinity chromatography, which matrix comprises said compound, as well as to other uses of the compound.

  本发明涉及一种IgG结合化合物，更具体地具有对人类κ型IgG及其功能衍生物的亲和力。更具体地，根据本发明，该化合物包括位于芳香部分和另一部分之间的N,N-烷基化脲基团，该另一部分是线性或环状取代或未取代的脂肪族基团。该化合物结合到所有人类IgG κ-Fab上存在的口袋状结合位点，该位点位于其恒定部分的两个域（CH1和CL）之间。因此，根据本发明，该化合物是人类κ型IgG的配体，因此，本发明还涉及一种亲和层析的分离基质，该基质包括所述化合物，以及该化合物的其他用途。
• Topical cosmetic treatment of skin and scalp and corresponding active ingredient based on an extract of Apium graveolens
  申请人：SEDERMA

  公开号：US10335354B2

  公开（公告）日：2019-07-02

  The invention provides the use of at least one alkyl-phthalide or a plant extract comprising mainly said alkyl-phthalide for the topical cosmetic treatment of the skin and of the scalp, in particular an anti-dandruff treatment. According to the invention, a CO2 supercritical extract of Apium graveolens seeds consisting mainly of sedanenolide may be used.

  本发明提供了至少一种烷基邻苯二甲酸酯或主要包含上述烷基邻苯二甲酸酯的植物提取物用于皮肤和头皮的局部美容治疗，特别是去屑治疗。根据本发明，可以使用主要由沉香烯内酯组成的芹菜种子二氧化碳超临界提取物。
• Topical cosmetic treatment of scalp and corresponding active ingredient based on an extract of Apium graveolens
  申请人：Sederma

  公开号：US11166897B2

  公开（公告）日：2021-11-09

  The invention provides a method for the topical non therapeutical cosmetic treatment of the scalp comprising applying to the scalp an effective amount of at least one alkyl-phthalide or a plant extract comprising mainly said alkyl-phthalide. In particular, the treatment is an anti-dandruff treatment. According to the invention, a CO2 supercritical extract of Apium graveolens seeds consisting mainly of sedanenolide may be used.

  本发明提供了一种对头皮进行局部非治疗性美容治疗的方法，该方法包括向头皮施用有效量的至少一种烷基邻苯二甲酸酯或主要包含上述烷基邻苯二甲酸酯的植物提取物。特别是，这种治疗是一种去屑治疗。根据本发明，可以使用主要由沉香烯内酯组成的芹菜种子二氧化碳超临界提取物。